ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.
IPO Year:
Exchange: NASDAQ
Website: essapharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/4/2024 | Buy → Hold | Jefferies | |
| 11/4/2024 | Outperform → Perform | Oppenheimer | |
| 11/4/2024 | $15.00 → $2.00 | Overweight → Neutral | Piper Sandler |
| 6/26/2023 | $17.00 | Outperform | Oppenheimer |
| 8/17/2021 | $36.00 → $22.00 | Outperform | Oppenheimer |